Basel Medical Group (NASDAQ:BMGL) Stock Rating Raised to “Hold” at Wall Street Zen

Basel Medical Group (NASDAQ:BMGL) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings lowered Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

Basel Medical Group Price Performance

Shares of NASDAQ BMGL opened at $5.29 on Friday. Basel Medical Group has a 52 week low of $2.56 and a 52 week high of $18.48. The company’s 50-day moving average price is $4.37 and its 200 day moving average price is $6.40.

Basel Medical Group (NASDAQ:BMGL) last posted its quarterly earnings data on Friday, October 30th. The company reported ($0.31) EPS for the quarter. The company had revenue of $3.14 million for the quarter.

Basel Medical Group Company Profile

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.